News of Note—New data for Fate’s off-the-shelf CAR-T in ALL; Nektar tests BMS-partnered drug in immuno-oncology … – FierceBiotech
FierceBiotech |
News of Note—New data for Fate's off-the-shelf CAR–T in ALL; Nektar tests BMS-partnered drug in immuno-oncology …
FierceBiotech Novartis's FDA-approved CAR–T treatment for acute lymphoblastic leukemia (ALL), Kymriah, is personalized to individual patients and targets the surface antigen CD19. Fate Therapeutics has been working on an alternative to Kymriah that the company hopes … |
